Which has higher earnings and valuation, DYN or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is DYN or JBIO more profitable?

Jade Biosciences' return on equity of -51.34% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Jade Biosciences N/A -51.34% -47.32%

Which has preferable earnings and valuation, GPCR or JBIO?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is GPCR or JBIO more profitable?

Structure Therapeutics' return on equity of -24.91% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Jade Biosciences N/A -51.34% -47.32%

Is RLAY or JBIO more profitable?

Relay Therapeutics' return on equity of -43.94% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Jade Biosciences N/A -51.34% -47.32%

Jade Biosciences (JBIO) Competitors

$21.90 -0.07 (-0.32%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$22.42 +0.53 (+2.40%)

As of 06/24/2026 06:51 PM Eastern

Compare

JBIO vs. ARQT, DYN, GPCR, RCUS, and RLAY

Should you buy Jade Biosciences stock or one of its competitors? MarketBeat compares Jade Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jade Biosciences include Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Arcus Biosciences (RCUS), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

How does Jade Biosciences compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Arcutis Biotherapeutics currently has a consensus target price of $34.00, suggesting a potential upside of 24.41%. Jade Biosciences has a consensus target price of $47.13, suggesting a potential upside of 115.18%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Arcutis Biotherapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Jade Biosciences has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Jade Biosciences	N/A	-51.34%	-47.32%

Arcutis Biotherapeutics has higher revenue and earnings than Jade Biosciences. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	9.09	-$16.14M	-$0.03	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 0 mentions for Jade Biosciences. Arcutis Biotherapeutics' average media sentiment score of 0.25 beat Jade Biosciences' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Neutral
Jade Biosciences	Neutral

Summary

Arcutis Biotherapeutics beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Dyne Therapeutics had 8 more articles in the media than Jade Biosciences. MarketBeat recorded 8 mentions for Dyne Therapeutics and 0 mentions for Jade Biosciences. Dyne Therapeutics' average media sentiment score of 0.53 beat Jade Biosciences' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dyne Therapeutics	Positive
Jade Biosciences	Neutral

96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dyne Therapeutics presently has a consensus target price of $33.85, indicating a potential upside of 66.48%. Jade Biosciences has a consensus target price of $47.13, indicating a potential upside of 115.18%. Given Jade Biosciences' higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -51.34% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Jade Biosciences	N/A	-51.34%	-47.32%

Jade Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

Summary

Dyne Therapeutics beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

In the previous week, Structure Therapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 1 mentions for Structure Therapeutics and 0 mentions for Jade Biosciences. Structure Therapeutics' average media sentiment score of 0.00 equaled Jade Biosciences'average media sentiment score.

Company	Overall Sentiment
Structure Therapeutics	Neutral
Jade Biosciences	Neutral

91.8% of Structure Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Structure Therapeutics has a beta of -1.35, indicating that its share price is 235% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Structure Therapeutics currently has a consensus target price of $110.55, indicating a potential upside of 129.54%. Jade Biosciences has a consensus target price of $47.13, indicating a potential upside of 115.18%. Given Structure Therapeutics' higher probable upside, equities analysts plainly believe Structure Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Structure Therapeutics' return on equity of -24.91% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Jade Biosciences	N/A	-51.34%	-47.32%

Structure Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Summary

Structure Therapeutics beats Jade Biosciences on 8 of the 13 factors compared between the two stocks.

How does Jade Biosciences compare to Arcus Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Jade Biosciences presently has a consensus price target of $47.13, suggesting a potential upside of 115.18%. Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 22.13%. Given Jade Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Jade Biosciences is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Jade Biosciences has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Jade Biosciences' return on equity of -51.34% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Jade Biosciences has higher earnings, but lower revenue than Arcus Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Arcus Biosciences	$247M	14.63	-$353M	-$3.18	N/A

Jade Biosciences has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

In the previous week, Arcus Biosciences had 6 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Arcus Biosciences and 0 mentions for Jade Biosciences. Arcus Biosciences' average media sentiment score of 1.67 beat Jade Biosciences' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Jade Biosciences	Neutral
Arcus Biosciences	Very Positive

92.9% of Arcus Biosciences shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Jade Biosciences beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Jade Biosciences (NASDAQ:JBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Relay Therapeutics had 3 more articles in the media than Jade Biosciences. MarketBeat recorded 3 mentions for Relay Therapeutics and 0 mentions for Jade Biosciences. Relay Therapeutics' average media sentiment score of 0.00 equaled Jade Biosciences'average media sentiment score.

Company	Overall Sentiment
Relay Therapeutics	Neutral
Jade Biosciences	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Jade Biosciences has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	225.07	-$276.48M	-$1.57	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Relay Therapeutics' return on equity of -43.94% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Jade Biosciences	N/A	-51.34%	-47.32%

Relay Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

Relay Therapeutics currently has a consensus target price of $23.30, suggesting a potential upside of 29.21%. Jade Biosciences has a consensus target price of $47.13, suggesting a potential upside of 115.18%. Given Jade Biosciences' higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Relay Therapeutics beats Jade Biosciences on 9 of the 13 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JBIO vs. The Competition

Export

Metric	Jade Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.08B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-10.84	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	3.25	8.26	10.76	6.41
Net Income	-$127.41M	$23.91M	$3.56B	$337.14M
7 Day Performance	29.82%	3.05%	1.37%	-0.48%
1 Month Performance	-1.40%	2.40%	0.81%	0.49%
1 Year Performance	108.97%	56.35%	30.53%	28.16%

Jade Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JBIO Jade Biosciences	2.6486 of 5 stars	$21.90 -0.3%	$47.13 +115.2%	+109.0%	$1.08B	N/A	N/A	20
ARQT Arcutis Biotherapeutics	3.7382 of 5 stars	$26.21 0.0%	$34.00 +29.7%	+90.7%	$3.28B	$376.07M	N/A	150	High Trading Volume
DYN Dyne Therapeutics	2.5806 of 5 stars	$19.80 +3.1%	$33.85 +70.9%	+91.3%	$3.27B	N/A	N/A	100	High Trading Volume
GPCR Structure Therapeutics	2.2028 of 5 stars	$44.51 -1.1%	$106.75 +139.8%	+115.2%	$3.16B	N/A	N/A	136
RCUS Arcus Biosciences	3.3705 of 5 stars	$24.39 +1.1%	$35.10 +43.9%	+227.9%	$3.07B	$247M	N/A	500	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jade Biosciences (JBIO) Competitors

JBIO vs. ARQT, DYN, GPCR, RCUS, and RLAY

How does Jade Biosciences compare to Arcutis Biotherapeutics?

Summary

How does Jade Biosciences compare to Dyne Therapeutics?

Summary

How does Jade Biosciences compare to Structure Therapeutics?

Summary

How does Jade Biosciences compare to Arcus Biosciences?

Summary

How does Jade Biosciences compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jade Biosciences (JBIO) Competitors

JBIO vs. ARQT, DYN, GPCR, RCUS, and RLAY

How does Jade Biosciences compare to Arcutis Biotherapeutics?

Do analysts rate ARQT or JBIO?

Which has more volatility & risk, ARQT or JBIO?

Is ARQT or JBIO more profitable?

Which has better valuation and earnings, ARQT or JBIO?

Does the media refer more to ARQT or JBIO?

Summary

How does Jade Biosciences compare to Dyne Therapeutics?

Does the media favor DYN or JBIO?

Do insiders & institutionals have more ownership in DYN or JBIO?

Do analysts rate DYN or JBIO?

Is DYN or JBIO more profitable?

Which has higher earnings and valuation, DYN or JBIO?

Which has more volatility & risk, DYN or JBIO?

Summary

How does Jade Biosciences compare to Structure Therapeutics?

Does the media favor GPCR or JBIO?

Do institutionals & insiders hold more shares of GPCR or JBIO?

Which has more volatility and risk, GPCR or JBIO?

Do analysts rate GPCR or JBIO?

Is GPCR or JBIO more profitable?

Which has preferable earnings and valuation, GPCR or JBIO?

Summary

How does Jade Biosciences compare to Arcus Biosciences?

Do analysts prefer JBIO or RCUS?

Is JBIO or RCUS more profitable?

Which has higher earnings & valuation, JBIO or RCUS?

Which has more volatility and risk, JBIO or RCUS?

Does the media refer more to JBIO or RCUS?

Do institutionals and insiders have more ownership in JBIO or RCUS?

Summary

How does Jade Biosciences compare to Relay Therapeutics?

Does the media refer more to RLAY or JBIO?

Do insiders and institutionals have more ownership in RLAY or JBIO?

Which has higher valuation and earnings, RLAY or JBIO?

Is RLAY or JBIO more profitable?

Which has more risk and volatility, RLAY or JBIO?

Do analysts recommend RLAY or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools